NEWPORT BEACH, Calif., June 11, 2026
Wave Neuroscience announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its MeRT® (Magnetic EEG-guided Resonance Therapy) System for the treatment of Post-Traumatic Stress Disorder (PTSD), making it the first FDA-cleared personalized, biomarker-guided neuromodulation platform for the condition. The landmark regulatory achievement establishes a new category in precision mental healthcare, leveraging individualized brain activity data to guide treatment delivery. Developed in collaboration with the Texas A&M Health Institute of Biosciences and Technology, the MeRT platform combines advanced EEG-based brain mapping, artificial intelligence-enhanced biomarker analysis, and personalized neuromodulation protocols designed to address the unique neurophysiology of each patient. The clearance represents a significant milestone in the evolution of non-invasive neurotechnology and could expand treatment options for millions of patients living with PTSD who continue to experience persistent symptoms despite conventional therapies.
Clinical Study Demonstrates Significant PTSD Symptom Reduction
The FDA clearance was supported by a double-blinded, randomized controlled multisite clinical trial conducted in partnership with investigators at Texas A&M Health. The study evaluated the safety and effectiveness of the MeRT System in patients diagnosed with PTSD and demonstrated clinically meaningful reductions in symptom severity following treatment. Unlike conventional neuromodulation approaches that typically apply standardized treatment protocols, MeRT utilizes each patient’s own EEG-derived biomarkers to customize therapy based on individual brain network activity patterns.
Researchers believe this personalized approach may help address the significant biological variability observed among PTSD patients, a factor that has historically complicated treatment outcomes. The FDA had previously granted the MeRT platform Breakthrough Device Designation in 2024, recognizing its potential to address a major unmet medical need within mental healthcare. The successful clearance validates years of research focused on integrating objective neurophysiological measurements into clinical decision-making.
Personalized Neuromodulation Advances Precision Psychiatry
Advertisement
At the core of the MeRT platform is an innovative approach to precision psychiatry, a rapidly growing field focused on tailoring treatment strategies to an individual’s unique biological characteristics. The technology combines AI-augmented EEG biomarker analysis with highly targeted neuromodulation protocols to optimize treatment delivery. By identifying abnormal neural network activity patterns associated with PTSD, clinicians can deliver individualized interventions designed to restore healthier brain function.
Experts believe this represents a substantial advancement over traditional symptom-based treatment models that rely primarily on subjective clinical assessments. The ability to measure and respond to objective brain activity data may improve treatment precision while enhancing patient outcomes. As demand grows for personalized and technology-enabled mental healthcare solutions, MeRT positions Wave Neuroscience at the forefront of next-generation neuropsychiatric treatment innovation.
FDA Clearance Supports Long-Term Growth and Market Expansion
Beyond its clinical significance, the FDA clearance establishes a strategic foundation for Wave Neuroscience’s future growth initiatives. The approval creates the company’s first FDA-cleared indication and provides a regulatory pathway for additional neurological and psychiatric applications involving dysregulated brain network activity. Company leadership believes the milestone will strengthen physician adoption, increase confidence among healthcare systems and referral networks, support payer engagement efforts, and accelerate institutional partnerships. The clearance also reinforces broader industry trends toward non-invasive, data-driven, and personalized healthcare technologies.
With PTSD affecting millions of military veterans, active-duty personnel, first responders, trauma survivors, and civilians worldwide, the availability of an FDA-cleared precision neuromodulation platform may significantly expand access to innovative treatment options. As precision brain health continues to emerge as a major area of medical innovation, Wave Neuroscience’s MeRT platform could play a pivotal role in shaping the future of personalized mental healthcare.
Source: Wave Neuroscience press release
